Merck & Co. MRK Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$4.24B-243% | $2.96B-48.8% | $5.79B+30.7% | $4.43B-12.9% | $5.09B+35.8% | ||
| $185M-9.8% | $205M+0.5% | $204M-5.6% | $216M+10.8% | $195M+4.3% | ||
| -$315M+61.8% | -$825M-289% | -$212M+52.7% | -$448M-141% | -$186M+69.8% | ||
| —— | $272.5M0.0% | $272.5M0.0% | $272.5M0.0% | $272.5M+347% | ||
| —— | $295M0.0% | $295M0.0% | $295M0.0% | $295M+41.3% | ||
| —— | $27.5M0.0% | $27.5M0.0% | $27.5M0.0% | $27.5M-39.6% | ||
| —— | -$460.25M0.0% | -$460.25M0.0% | -$460.25M0.0% | -$460.25M+20.9% | ||
| —— | $48.75M0.0% | $48.75M0.0% | $48.75M0.0% | $48.75M+498% | ||
| —— | $34.25M0.0% | $34.25M0.0% | $34.25M0.0% | $34.25M-86.6% | ||
| $3.92B+37.1% | $2.86B-63.5% | $7.82B+138% | $3.29B+31.7% | $2.5B-27.5% | ||
| $991M-4.1% | $1.03B+4.7% | $987M+29.2% | $764M-42.5% | $1.33B+41.7% | ||
| $8.78B-12.6% | $10.04B— | $0— | $0— | $0+100% | ||
| $374M— | —— | —— | $612M+2.9% | $595M+30.8% | ||
| -$10.21B+8.8% | -$11.2B-3,858% | -$283M+63.2% | -$770M+48.2% | -$1.49B-3.0% | ||
| $2.11B+4.3% | $2.02B-0.6% | $2.03B-2.2% | $2.08B+1.3% | $2.05B+5.1% | ||
| $874M-30.2% | $1.25B-5.4% | $1.32B-1.6% | $1.35B+15.5% | $1.16B+138% | ||
| $1.14B+56,900% | $2M+100% | $1M— | $0-100% | $2.5B+364% | ||
| $157M+234% | $47M+236% | $14M+16.7% | $12M-36.8% | $19M+58.3% | ||
| -$2.98B— | —— | —— | -$3.56B+38.2% | -$5.76B-91.3% | ||
| -$19M-183% | $23M+130% | $10M-97.3% | $374M+140% | $156M+143% | ||
| -$9.29B— | —— | $10.19B+1,646% | -$659M+85.6% | -$4.59B— | ||
| -$20M+83.1% | -$118M— | $0+100% | -$335M-207% | -$109M— | ||
| $931M-4.3% | $973M+56.4% | $622M+3.5% | $601M+0.7% | $597M-11.6% | ||
| $581M-61.1% | $1.49B+181% | $532M+2.7% | $518M+3.2% | $502M-3.8% | ||
| $168M— | —— | $373M+273% | $100M+11.1% | $90M— | ||
| —— | $27.5M0.0% | $27.5M0.0% | $27.5M0.0% | $27.5M-39.6% | ||
| $1.61B— | —— | —— | $2.26B-39.1% | $3.71B— | ||
| -$20M+83.1% | -$118M— | $0+100% | -$335M-207% | -$109M— | ||
| $8.54B— | $0— | $0— | $0— | $0-100% | ||
| $66M-61.6% | $172M+233% | -$129M— | $0-100% | $20M-64.9% | ||
| —— | $0— | $0— | $0— | $0— | ||
| —— | $0— | $0— | $0— | $0— | ||
| -$80M— | —— | —— | -$194M-223% | -$60M-42.9% | ||
| $1.06B— | —— | $15M-68.8% | $48M— | $0— | ||
| $2.93B+60.5% | $1.82B-73.3% | $6.84B+170% | $2.53B+116% | $1.17B-53.4% | ||
| $2.93B+60.5% | $1.82B-73.3% | $6.84B+170% | $2.53B+116% | $1.17B-53.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Merck & Co. generate?
- Merck & Co. (MRK) generated $17.9B in operating cash flow over the trailing twelve months.
- What is Merck & Co.'s free cash flow?
- After $3.8B of capital expenditures, Merck & Co.'s free cash flow was $14.1B over the trailing twelve months, down 17.2% year over year.
- Where does Merck & Co.'s cash flow data come from?
- Every line is extracted from Merck & Co.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
